Piperidinylamino-thieno[2,3-D] pyrimidine compounds

Details Piperidinylamino-thieno[2,3-D] pyrimidine compounds Piperidinylamino-thieno[2,3-D] pyrimidine compounds

2005-03-08

2009-11-03

Coleman, Brenda L (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S278000

Reexamination Certificate

active

07612078

ABSTRACT:
The invention relates to 5-HT receptor modulators, particularly 5-HT2Bantagonists. Novel piperidinylamino-thieno[2,3-d]pyrimidine compounds represented by Formula I, II and III, and uses thereof for treating conditions including pulmonary arterial hypertension, congestive heart failure, and hypertension.

REFERENCES:
patent: 3069412 (1962-12-01), Roberts et al.
patent: 3658807 (1972-04-01), Schmidt et al.
patent: 4146716 (1979-03-01), Cox et al.
patent: 4316020 (1982-02-01), Reissenweber et al.
patent: 5155155 (1992-10-01), Jurlaro
patent: 5219864 (1993-06-01), Suzuki et al.
patent: 5227387 (1993-07-01), Dreikorn et al.
patent: 5236917 (1993-08-01), Dunlap et al.
patent: 5371074 (1994-12-01), Dunlap et al.
patent: 5378679 (1995-01-01), Nuebling et al.
patent: 5571815 (1996-11-01), Schaper et al.
patent: 5591751 (1997-01-01), Fujioka et al.
patent: 5593943 (1997-01-01), Nuebling et al.
patent: 5596012 (1997-01-01), Dunlap et al.
patent: 5650422 (1997-07-01), Dunlap et al.
patent: 5753673 (1998-05-01), Ohuchi et al.
patent: 5798451 (1998-08-01), von Deyn et al.
patent: 5874432 (1999-02-01), Dunlap et al.
patent: 5972841 (1999-10-01), von Deyn et al.
patent: 6103903 (2000-08-01), Cai et al.
patent: 6159962 (2000-12-01), Steiner et al.
patent: 6187788 (2001-02-01), Furuya et al.
patent: 6222034 (2001-04-01), Steiner et al.
patent: 6232320 (2001-05-01), Stewart et al.
patent: 6300333 (2001-10-01), Schaper et al.
patent: 6340759 (2002-01-01), Ueno et al.
patent: 6596727 (2003-07-01), Schaper et al.
patent: 6924283 (2005-08-01), Thorarensen
patent: 7030240 (2006-04-01), Dhanoa et al.
patent: 7119205 (2006-10-01), Iyengar et al.
patent: 7153858 (2006-12-01), Dhanoa et al.
patent: 2004/0138238 (2004-07-01), Dhanoa et al.
patent: 2005/0049243 (2005-03-01), Ballard et al.
patent: 2005/0065176 (2005-03-01), Field et al.
patent: 2005/0137142 (2005-06-01), Schulz et al.
patent: 2005/0222175 (2005-10-01), Dhanoa et al.
patent: 2005/0256153 (2005-11-01), Dhanoa et al.
patent: 2006/0079547 (2006-04-01), Dhanoa et al.
patent: 2006/0084805 (2006-04-01), Dhanoa et al.
patent: 2006/0084806 (2006-04-01), Sridharan et al.
patent: 2006/0205737 (2006-09-01), Becker et al.
patent: 2006/0234998 (2006-10-01), Dhanoa et al.
patent: 2007/0004742 (2007-01-01), Dhanoa et al.
patent: 2007/0173487 (2007-07-01), Saha et al.
patent: 0447891 (1991-09-01), None
patent: 0503844 (1992-09-01), None
patent: 0505058 (1992-09-01), None
patent: 0710662 (1996-05-01), None
patent: 1018513 (2000-07-01), None
patent: 0710662 (2001-04-01), None
patent: 1 229 025 (2002-08-01), None
patent: 1325921 (2003-07-01), None
patent: 1018513 (2004-07-01), None
patent: 1018513 (2006-02-01), None
patent: 2 295 387 (1996-05-01), None
patent: 11130777 (1999-05-01), None
patent: WO 94/12176 (1994-06-01), None
patent: WO 94/22871 (1994-10-01), None
patent: WO 00/64441 (2000-11-01), None
patent: WO 01/14333 (2001-03-01), None
patent: WO 01/25218 (2001-04-01), None
patent: WO 02/102797 (2002-12-01), None
patent: WO 2004/014850 (2004-02-01), None
patent: WO 2004/017950 (2004-03-01), None
patent: WO 2004/030629 (2004-04-01), None
patent: WO 2004/034963 (2004-04-01), None
patent: WO 2004/089312 (2004-10-01), None
patent: WO 2005/121151 (2005-12-01), None
patent: WO 2006/041985 (2006-04-01), None
patent: WO 2007/058805 (2007-05-01), None
Barker et al., Journal of Chemical Research, Synopses, 1985 (7) 214-15.
Bonhaus, D.W., et al., British J. Pharmac., 1999 (127) 1075-1082.
Buchheit et al., J. Med. Chem., 1995 (38) 2326-2330.
Buchheit et al., J. Med. Chem., 1995 (38) 2331-2338.
Buchstaller, H.P., et al., Scientia Pharmazeutica, 2000 (68) 3-14.
Coppola et al., Journal of Organic Chemistry, 1976 (41) 825-831.
International Search Report for PCT/US2003/23539 mailed Jul. 23, 2004.
Database Caplus on STN, Accession No. 1999:783937, Castelhano et al., WO 99/62518 A1, Cadue Pharmaceuticals Corp. Dec. 9, 1999.
Database Caplus on STN, Accession No. 2000:806616 Horvath, et al., Neurogen Corporation. 6,147,085, Nov. 14, 2000.
Doggrell, Sheila A., Expert Opin. Investig. Drugs, 2003 (12) 805-823.
Gordon W. Gribble, Sodium Borohydride in Carboxylic Acid Media: A Phenomenal Reduction System, Chemical Society Reviews, 1998 (27) 395-40.
Hutchins, R.O., et al., J. Org. Chem., 1977 (42) 82-91.
Hwang et al., Arch. of Pharm. Res., 2001, 24(4), 270-275.
International Search Report for PCT/US2004/09944 mailed Mar. 1, 2005.
International Search Report for PCT/US2005/034862 mailed Jan. 24, 2006.
International Search Report for PCT/US2005/17121 mailed Apr. 4, 2006.
Jerry March in Advanced Organic Chemistry 4th Edition, 1992, by John Wiley & Sons: New York, pp. 378-383.
Kaumann, A.J., Naunyn-Schmiedeberg's Arch. Pharmacol., 342: 619-622 (1990).
Lamirault, L., et al., Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2003 (27) 185-195.
Moser, P. C., et al., The Journal of Pharmacology and Experimental Therapeutics, 302: 731-741, 2002.
Recanatini, M., et al., Acetylcholinesterase Inhibitors in the Context of Therapeutic Strategies to Combat Alzheimer's Disease, Expert Opinion on Therapeutic Patents, Ashley Publications, GB, vol. 12, No. 12, 2002, pp. 1853-1865.
Roth, B. L., et al., Expert Opin. Ther. Targets, 2001 (5) 685-695.
Science IP Search, Apr. 30, 2004.
Science IP Search, May 11, 2004.
Suzuki, M., Chem Pharm. Bull., 2001 (49) 29-39.
Tojo et al., Bioorganic & Medicinal Chemistry Letters, 2002 (12) 2427-2430.
International Search Report for PCT/US2006/043140 mailed Aug. 16, 2007.
International Search Report for PCT/US2005/035935 mailed May 12, 2006.
Abenhaim et al.N. Engl.J. Med., 335(9):609-616 (1996).
Brea et al.J. Med. Chem., 45:54-71 (2002).
Farber et al.N. Engl. J. Med., 351(16):1655-1665 (2004).
FishmanCHEST, 114(3):242S-247S (1998).
Fitzgerald et al.Mol. Pharmacol., 57:75-81 (2000).
Kennett et al.Neuropharmacol., 36(2):233-239 (1997).
Kursar et al.Mol. Pharmacol., 46(2):227-234 (1994).
Kuryshev et al.J. Pharmacol. Exp. Ther., 295(2):614-620 (2000).
Launay et al.Nat. Med., 8(10):1129-1135 (2002).
MacLeanTrends Pharmacol. Sci., 20(12):490-495 (1999).
Manivet et al.J. Biol. Chem., 277(19):17170-17178 (2002).
Marcos et al.Circ. Res., 94:1263-1270 (2004).
Nauser et al.Am. Fam. Physician, 63(9):1789-1798 (2001).
Nebigil et al.Proc. Natl. Acad. Sci. U.S.A., 97(6):2591-2596 (2000).
Poissonnet et al.Mini-Rev. Med. Chem., 4(3):325-330 (2004).
Rich et al.CHEST, 117(3):870-874 (2000).
Rothman et al.Circulation, 102:2836-2841 (2000).
Setola et al.Mol. Pharmacol., 63(6):1223-1229 (2003).
Teoh et al., “Hypoxia Enhances 5-HT2BReceptor Response and Expression in the Rat Pulmonary Artery”, Abstract only,International Conference of the American Thoracic Society, San Diego (May 24, 2005).
Ullmer et al.Br. J. Pharmacol., 117(6):1081-1088 (1996).
Ullmer et al.FEBS Lett., 370(3):215-221 (1995).
Witchel et al.J. Clin. Psychopharmacol., 23(1):58-77 (2003).
Witchel et al.FEBS Lett., 512(1-3):59-66 (2002).
Yamada et al.Eur. J. Pharmacol., 406(1):153-157 (2000).
Audia et al.,J. Med. Chem.1996, 39, 2773-2780.
Watts et al.,Am. J. Physiol. Heart Circ. Physiol.1999, 276, 944-952.
Russell et al.,The Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 179-187.
Schmuck et al.,European Journal of Neuroscience, 1996, 8, 959-967.
Borman et al.,British Journal of Pharmacology, 2002, 135, 1144-1151.
Bromidge et al.,J. Med. Chem., 1998, 41, 1598-1612.
Stachel, Hans-Dietrich, et al., Liebigs Annalen der Chemie (1994), 11, 1121-27. Abstract.

Affiliated with

Also associated with

Rating

Piperidinylamino-thieno[2,3-D] pyrimidine compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Piperidinylamino-thieno[2,3-D] pyrimidine compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperidinylamino-thieno[2,3-D] pyrimidine compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4085699